The role of genomics in the discovery of novel targets for antibiotic therapy.

Abstract:

:The emergence of antibiotic resistance and multi-drug resistance in bacterial pathogens underscores the need for the development of novel classes of antibiotics. The availability of complete genome sequence data from many important human pathogens provides a wealth of fundamental information. This allows us to define each gene and thus to better understand molecular pathogenesis. New techniques have enabled the identification and characterization of genes that are critical for bacterial growth and survival during infection. The combination of genome sequence data and new technologies make it possible to systematically explore the function of each open reading frame in a genome and identify any potential molecular targets for drug discovery. With particular emphasis on antibacterial therapy, this review discusses genome-based technologies and their important applications to anti-infective drug discovery.

journal_name

Pharmacogenomics

journal_title

Pharmacogenomics

authors

Ji Y

doi

10.1517/14622416.3.3.315

keywords:

subject

Has Abstract

pub_date

2002-05-01 00:00:00

pages

315-23

issue

3

eissn

1462-2416

issn

1744-8042

pii

PGS030306

journal_volume

3

pub_type

杂志文章,评审
  • Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance.

    abstract:OBJECTIVES:Three exonic single nucleotide polymorphisms (SNPs) in the cytochrome P450 2B6 (CYP2B6) gene, 516G>T, 785A>G and 1459C>T, have been described to be associated with functional changes in the CYP2B6 catalytic activity or protein expression. They are therefore of potential clinical importance for drug efficacy ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.7.7.995

    authors: Rohrbacher M,Kirchhof A,Geisslinger G,Lötsch J

    更新日期:2006-10-01 00:00:00

  • Differential sensitivity of mouse strains to an N-alkylated imino sugar: glycosphingolipid metabolism and acrosome formation.

    abstract::This review deals with the pharmacological properties of an alkylated monosaccharide mimetic, N-butyldeoxynojirimycin (NB-DNJ). This compound is of pharmacogenetic interest because one of its biological effects in mice - impairment of spermatogenesis, leading to male infertility - depends greatly on the genetic backgr...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.9.6.717

    authors: van der Spoel AC,Mott R,Platt FM

    更新日期:2008-06-01 00:00:00

  • Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke.

    abstract:BACKGROUND & METHODS:Economic evaluation in genomic medicine is an emerging discipline to assess the cost-effectiveness of genome-guided treatment. Here, we developed a pharmaco-economic model to assess whether pharmacogenomic (PGx)-guided warfarin treatment of elderly ischemic stroke patients with atrial fibrillation ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,随机对照试验

    doi:10.2217/pgs.14.167

    authors: Mitropoulou C,Fragoulakis V,Bozina N,Vozikis A,Supe S,Bozina T,Poljakovic Z,van Schaik RH,Patrinos GP

    更新日期:2015-01-01 00:00:00

  • Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer.

    abstract::Recent advances in next-generation sequencing techniques have greatly improved our understanding of the genomic alterations in bladder cancer. Cisplatin-based chemotherapy provides a viable treatment option in the neoadjuvant, adjuvant and metastatic setting in a selected group of patients, but chemoresistance is a ma...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2017-0055

    authors: Zuiverloon TC,Theodorescu D

    更新日期:2017-08-01 00:00:00

  • Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease.

    abstract::The potential for personalized sequencing to individually optimize medical treatment in diseases such as cancer and for pharmacogenomic application is just beginning to be realized, and the utility of sequencing healthy individuals for managing health is also being explored. The data produced requires additional advan...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.117

    authors: Esplin ED,Oei L,Snyder MP

    更新日期:2014-11-01 00:00:00

  • Clinical pharmacogenetics: how do we ensure a favorable future for patients?

    abstract::Currently, there is sufficient evidence for the use of pharmacogenetic information to optimize medication prescribing, but why has this information not been integrated into the drug prescribing process to improve patient care? A discussion about the major contributing factors that have limited the use of pharmacogenet...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2017-0192

    authors: Wiltshire T,Dong OM

    更新日期:2018-04-01 00:00:00

  • Genomics, complexity and drug discovery: insights from Boolean network models of cellular regulation.

    abstract::The completion of the first draft of the human genome sequence has revived the old notion that there is no one-to-one mapping between genotype and phenotype. It is now becoming clear that to elucidate the fundamental principles that govern how genomic information translates into organismal complexity, we must overcome...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.2.3.203

    authors: Huang S

    更新日期:2001-08-01 00:00:00

  • The pharmacogenetics of NAT: structural aspects.

    abstract::Arylamine N-acetyltransferases (NATs) catalyze the transfer of an acetyl group from acetyl-CoA to arylhydrazines and to arylamine drugs and carcinogens or to their N-hydroxylated metabolites. NAT plays an important role in detoxification and metabolic activation of xenobiotics and was first identified as the enzyme re...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.3.1.19

    authors: Pompeo F,Brooke E,Kawamura A,Mushtaq A,Sim E

    更新日期:2002-01-01 00:00:00

  • Psychiatric pharmacists' perception on the use of pharmacogenomic testing in the mental health population.

    abstract:AIM:Pharmacogenomics could play a role in improving patient care, reducing adverse drug reactions and overall healthcare costs. However, whether it is utilized may be determined by how it is perceived by healthcare professionals, including pharmacists. METHODS:A cross-sectional web-based survey evaluated psychiatric p...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.15.22

    authors: Shishko I,Almeida K,Silvia RJ,Tataronis GR

    更新日期:2015-01-01 00:00:00

  • CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen.

    abstract:AIMS:Variant alleles of the CYP2C19 gene were recently associated with survival in breast cancer patients on tamoxifen therapy. CYP2C19 is one of the enzymes involved in the metabolism of tamoxifen into active metabolites. We investigated the hypothesis that CYP2C19*2 and *3 variants, known for their lack of enzyme act...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.10.112

    authors: Ruiter R,Bijl MJ,van Schaik RH,Berns EM,Hofman A,Coebergh JW,van Noord C,Visser LE,Stricker BH

    更新日期:2010-10-01 00:00:00

  • Meta-analysis in genome-wide association studies.

    abstract::The advent of genome-wide association studies has allowed considerable progress in the identification and robust replication of common gene variants that confer susceptibility to common diseases and other phenotypes of interest. These genetic effect sizes are almost invariably moderate to small in magnitude and single...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.10.2.191

    authors: Zeggini E,Ioannidis JP

    更新日期:2009-02-01 00:00:00

  • Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain.

    abstract:AIM:GLP-1 plays a key role in glucose metabolism and influences antipsychotic-induced weight gain (AIWG). Our study is the first to investigate the encoding gene, GCG, and the GLP-1 receptor gene, GLP1R, and association with AIWG. MATERIALS & METHODS:In 216 schizophrenic patients treated with antipsychotics for up to ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.13.247

    authors: Brandl EJ,Tiwari AK,Chowdhury NI,Zai CC,Lieberman JA,Meltzer HY,Kennedy JL,Müller DJ

    更新日期:2014-03-01 00:00:00

  • Clinical consequences of ADRbeta2 polymorphisms.

    abstract::The most prescribed medication for controlling bronchoconstriction associated with asthma and chronic obstructive pulmonary disease are beta-agonists. The gene ADRbeta2 encodes the beta-2-adrenergic receptor and contains several common genetic variations that affect gene expression and receptor function in vitro. The ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.9.3.349

    authors: Hawkins GA,Weiss ST,Bleecker ER

    更新日期:2008-03-01 00:00:00

  • Genomic architecture of pharmacological efficacy and adverse events.

    abstract::The pharmacokinetic and pharmacodynamic disciplines address pharmacological traits, including efficacy and adverse events. Pharmacogenomics studies have identified pervasive genetic effects on treatment outcomes, resulting in the development of genetic biomarkers for optimization of drug therapy. Pharmacogenomics-base...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.14.144

    authors: Chhibber A,Kroetz DL,Tantisira KG,McGeachie M,Cheng C,Plenge R,Stahl E,Sadee W,Ritchie MD,Pendergrass SA

    更新日期:2014-12-01 00:00:00

  • Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.

    abstract::Mother-to-child-transmission rates of HIV in the absence of any intervention range between 20 and 45%. However, the provision of antiretroviral drugs (ARVs) during pregnancy, delivery and breastfeeding can reduce HIV transmission to less than 2%. Physiological changes during pregnancy can influence ARV disposition. As...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.12.138

    authors: Olagunju A,Owen A,Cressey TR

    更新日期:2012-10-01 00:00:00

  • Genetic variability of CYP2C9*2 and CYP2C9*3 in seven indigenous groups from Mexico.

    abstract:AIM:CYP2C9 is one of the major drug metabolizing enzymes, however, little is known about polymorphisms in CYP2C9 gene and pharmacological implications in Mexican indigenous populations. Thus, frequencies of CYP2C9*2 and CYP2C9*3 alleles were evaluated in indigenous groups located in northwest (Cora), center (Mazahua an...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2016-0099

    authors: Sánchez-Pozos K,Rivera-Santiago C,García-Rodríguez MH,Ortiz-López MG,Peña-Espinoza BI,Granados-Silvestre MLÁ,Llerena A,Menjívar M

    更新日期:2016-11-01 00:00:00

  • Implications of the incidentalome for clinical pharmacogenomics.

    abstract::Incidental findings have long posed challenges for healthcare providers, but the scope and scale of these challenges have increased with the introduction of new technologies. This article assesses the impact of incidental findings on the introduction of prospective pharmacogenomic testing into clinical use. Focusing o...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.13.119

    authors: Brothers KB,Langanke M,Erdmann P

    更新日期:2013-08-01 00:00:00

  • Pharmacogenomics and the treatment of acute myeloid leukemia.

    abstract::Acute myeloid leukemia (AML) is a clinically and biologically heterogeneous malignancy that is primarily treated with combinations of cytarabine and anthracyclines. Although this scheme remains effective in most of the patients, variability of outcomes in patients has been partly related with their genetic variability...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2016-0055

    authors: Megías-Vericat JE,Montesinos P,Herrero MJ,Bosó V,Martínez-Cuadrón D,Poveda JL,Sanz MÁ,Aliño SF

    更新日期:2016-07-01 00:00:00

  • Discovery Partners International.

    abstract::Discovery Partners International (Nasdaq: DPII) is a leader in collaborative drug discovery. DPI's integrated discovery framework encompasses a broad spectrum of capabilities in chemistry, biology, informatics, computational modeling and synthesis automation. DPI's approach to drug discovery places a heavy emphasis on...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.1517/14622416.3.1.145

    authors: Herd C

    更新日期:2002-01-01 00:00:00

  • Requirements for comprehensive pharmacogenetic genotyping platforms.

    abstract::Recent research highlighted the large extent of rare variants in pharmacogenes and, on this basis, it was estimated that rare variants account for 30-40% of the functional variability in pharmacogenes. It has been proposed that comprehensive next-generation sequencing (NGS)-based sequencing of pharmacogenes could soon...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2016-0023

    authors: Lauschke VM,Ingelman-Sundberg M

    更新日期:2016-06-01 00:00:00

  • Implementation of a pharmacogenomic program in a Brazilian public institution.

    abstract::This narrative review describes implementation, current status and perspectives of a pharmacogenomic (PGx) program at the Brazilian National Cancer Institute (INCA), targeting the cancer chemotherapeutic drugs - fluoropyrimidines, irinotecan and thiopurines. This initiative, designed as a research project, was support...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2020-0016

    authors: Suarez-Kurtz G,Kovaleski G,Elias AB,Motta V,Wolch K,Emerenciano M,Mansur MB,Palladino AM,Accioly MT,Ferreira M,Gonçalves AA,de Melo AC

    更新日期:2020-06-01 00:00:00

  • Pharmacogenomics and bioinformatics: PharmGKB.

    abstract::The NIH initiated the PharmGKB in April 2000. The primary mission was to create a repository of primary data, tools to track associations between genes and drugs, and to catalog the location and frequency of genetic variations known to impact drug response. Over the past 10 years, new technologies have shifted researc...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.10.15

    authors: Thorn CF,Klein TE,Altman RB

    更新日期:2010-04-01 00:00:00

  • Parkinson's disease pharmacogenomics: new findings and perspectives.

    abstract::Parkinson's disease (PD) is unique among neurodegenerative disorders because a highly effective pharmacological symptomatic treatment is available. The marked variability in drug response and in adverse profiles associated with this treatment led to the search of genetic markers associated with these features. We pres...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.14.93

    authors: Schumacher-Schuh AF,Rieder CR,Hutz MH

    更新日期:2014-06-01 00:00:00

  • 677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis.

    abstract:INTRODUCTION:Methotrexate (MTX), widely used in the treatment of rheumatoid arthritis (RA), inhibits dihydrofolate reductase and folate-dependent enzymes. Methylenetetrahydrofolate reductase (MTHFR) is involved in folate metabolism and has been shown to be polymorphic, affecting the enzyme activity. METHODS:To examine...

    journal_title:Pharmacogenomics

    pub_type: 临床试验,杂志文章

    doi:10.2217/14622416.8.11.1551

    authors: Kurzawski M,Pawlik A,Safranow K,Herczynska M,Drozdzik M

    更新日期:2007-11-01 00:00:00

  • International warfarin genotype-guided dosing algorithms in the Turkish population and their preventive effects on major and life-threatening hemorrhagic events.

    abstract:AIM:To determine the accuracy of international warfarin pharmacogenetic algorithms developed on large multiethnic cohorts (comprising more than 1000 subjects) to predict therapeutic warfarin doses in Turkish patients. MATERIALS & METHODS:We investigated two Turkish warfarin-treated cohorts: patients with no history of...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.15.58

    authors: Karaca S,Bozkurt NC,Cesuroglu T,Karaca M,Bozkurt M,Eskioglu E,Polimanti R

    更新日期:2015-01-01 00:00:00

  • The impact of HER2 overexpression on the miRNA and circRNA transcriptomes in two breast cell lines and their vesicles.

    abstract::HER2 upregulation is related with poor outcome in many tumor types. Whereas anti-HER2 treatment is the standard approach as adjuvant therapy in HER2-overexpressing breast cancer, the frequent relapses reinforce the need for alternative treatments. Here we used next-generation sequencing (NGS) to evaluate miRNAs and ci...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2018-0182

    authors: Galli de Amorim M,Branco G,Valieris R,Tarcitano E,Tojal da Silva I,Ferreira de Araújo L,Noronha Nunes D,Dias-Neto E

    更新日期:2019-05-01 00:00:00

  • Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program.

    abstract::In this report, we review the importance of pharmacovigilance in detecting postmarketing adverse drug events and the potential for developing pharmacogenovigilance programs by integrating pharmacogenomics with pharmacovigilance. We propose to start developing such a program in primary healthcare systems that use basic...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.14.44

    authors: Awada Z,Zgheib NK

    更新日期:2014-04-01 00:00:00

  • Information management systems for pharmacogenomics.

    abstract::The value of high-throughput genomic research is dramatically enhanced by association with key patient data. These data are generally available but of disparate quality and not typically directly associated. A system that could bring these disparate data sources into a common resource connected with functional genomic...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.3.5.651

    authors: Thallinger GG,Trajanoski S,Stocker G,Trajanoski Z

    更新日期:2002-09-01 00:00:00

  • Cambridge Healthtech Institute's Third Annual Conference on Lab-on-a-Chip and Microarrays. 22-24 January 2001, Zurich, Switzerland.

    abstract::Cambridge Healthtech Institute's Third Annual Conference on Lab-on-a-Chip and Microarray technology covered the latest advances in this technology and applications in life sciences. Highlights of the meetings are reported briefly with emphasis on applications in genomics, drug discovery and molecular diagnostics. Ther...

    journal_title:Pharmacogenomics

    pub_type:

    doi:10.1517/14622416.2.1.73

    authors: Jain KK

    更新日期:2001-02-01 00:00:00

  • SimuGen Ltd: reliable, early prediction of drug toxicity with toxicogenomics, human cell culture and computational models.

    abstract::Toxicogenomics is, arguably, the most exciting endeavor to better understand and/or predict the toxicity of drugs during their development, using technologies such as gene-expression microarrays. Through much of its (sometimes overzealous) build-up, toxicogenomics has found a natural niche as a bioinformatics and/or p...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.8.8.1081

    authors: Wills Q

    更新日期:2007-08-01 00:00:00